Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors.
C. Sessa(Vita-Salute San Raffaele University), Luca Gianni(Fondazione Michelangelo), Michela Miani, Amalia Florez, Elisa Gallerani, A. Christinat, Carlos Fernández, Gianluca Del Conte(IRCCS Ospedale San Raffaele), Antonella Perotti(European Institute of Oncology), Carmen Kahatt, Pilar Lardelli(Roche (Switzerland))
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
|Annals of Oncology|2022|382
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|288